Patents by Inventor Cheri Blum

Cheri Blum has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • RAF KINASE INHIBITORS
    Publication number: 20120178780
    Abstract: Methods of treating tumors mediated by raf kinase, with substituted urea compounds, and such compounds per se.
    Type: Application
    Filed: March 19, 2012
    Publication date: July 12, 2012
    Inventors: Jill E. WOOD, Hanno Wild, Daniel H. Rogers, John Lyons, Michael Katz, Yolanda Caringal, Robert Dally, Wendy Lee, Roger A. Smith, Cheri Blum
  • Raf Kinase Inhibitors
    Publication number: 20100063088
    Abstract: Methods of treating tumors mediated by raf kinase, with substituted urea compounds, and such compounds per se.
    Type: Application
    Filed: November 17, 2009
    Publication date: March 11, 2010
    Inventors: Jill E. WOOD, Hanno Wild, Daniel H. Rogers, John Lyons, Michael Katz, Yolanda Caringal, Robert Dally, Wendy Lee, Roger A. Smith, Cheri Blum
  • Raf kinase inhibitors
    Publication number: 20050256174
    Abstract: Methods of treating tumors mediated by raf kinase, with substituted urea compounds, and such compounds per se.
    Type: Application
    Filed: June 10, 2005
    Publication date: November 17, 2005
    Inventors: Jill Wood, Hanno Wild, Daniel Rogers, John Lyons, Michael Katz, Yolanda Caringal, Robert Dally, Wendy Lee, Roger Smith, Cheri Blum
  • Purine inhibitors of cyclin dependent kinase 2 and IkappaB-alpha
    Publication number: 20050080261
    Abstract: Compounds of the following formula are provided: In the Formula (I), R1 is —X—R1?; in which R1? is optionally substituted lower alkyl, optionally substituted aryl, optionally substituted heteroaryl, or optionally substituted heterocyclyl, and X is —NH—. R2 is lower alkyl optionally substituted with one, two or three groups chosen from hydroxy, lower alkoxy, and halogen. And R3 is —NR4R5; in which R4 is hydrogen and R5 is lower alkyl substituted with amino; or (ii) R4 and R5 are both lower alkyl optionally substituted with one, two or three groups chosen from hydroxy and amino. It is to be understood that R1? is not cyclohexylmethyl, phenyl, substituted phenyl, benzyl, phenylethyl, or m-hydroxybenzyl. The compounds inhibit CDK-2 activity and are useful for treating disorders characterized by undesirable cell proliferation.
    Type: Application
    Filed: March 3, 2004
    Publication date: April 14, 2005
    Inventors: Robert Lum, Cheri Blum, Richard Mackman, Michael Wick, Steven Schow, Jeffery Zablocki, Prabha Ibrahim
  • Raf kinase inhibitors
    Publication number: 20010006975
    Abstract: Methods of treating tumors mediated by raf kinase, with substituted urea compounds, and such compounds per se.
    Type: Application
    Filed: January 8, 2001
    Publication date: July 5, 2001
    Applicant: BAYER CORPORATION and ONYX PHARMACEUTICALS West Haven, CT and Richmond, CA, respectively
    Inventors: Jill E. Wood, Hanno Wild, Daniel H. Rogers, John Lyons, Michael Katz, Yolanda Caringal, Robert Dally, Wendy Lee, Roger A. Smith, Cheri Blum
  • Inhibition of raf kinase activity using aryl ureas
    Patent number: 6187799
    Abstract: Methods of treating tumors mediated by raf kinase, with substituted urea compounds, and such compounds per se.
    Type: Grant
    Filed: May 22, 1998
    Date of Patent: February 13, 2001
    Assignees: Onyx Pharmaceuticals, Bayer Corporation
    Inventors: Jill E Wood, Hanno Wild, Daniel H Rogers, John Lyons, Michael Katz, Yolanda Caringal, Robert Dally, Wendy Lee, Roger A. Smith, Cheri Blum